Calcipotriol
- Generic Name
- Calcipotriol
- Brand Names
- Calcitrene, Dovobet, Dovonex, Enstilar, Sorilux, Taclonex, Wynzora
- Drug Type
- Small Molecule
- Chemical Formula
- C27H40O3
- CAS Number
- 112965-21-6
- Unique Ingredient Identifier
- 143NQ3779B
- Background
Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.
- Indication
For the treatment of moderate plaque psoriasis in adults.
- Associated Conditions
- Plaque psoriasis of the scalp, Psoriasis Vulgaris (Plaque Psoriasis)
Lipidor's Phase III Psoriasis Trial Reaches Halfway Enrollment Mark, Results Expected in April
• Lipidor AB has announced that half of the patients have been randomized in its Phase III clinical study of AKP02G2 for mild to moderate psoriasis.
• The study, involving 294 patients across 15 clinics, compares AKP02G2 to a market-leading psoriasis treatment.
• Patient recruitment is expected to be completed in February, with topline results anticipated in April 2025.
• The company's CEO, Ola Holmlund, noted that reaching the halfway mark is a significant milestone, with all clinics now actively recruiting.
Endo and Paladin Pharma Partner to Launch Wynzora Cream in Canada for Plaque Psoriasis
• Endo, through its subsidiary Paladin Pharma, has partnered with MC2 Therapeutics to introduce Wynzora Cream to the Canadian market.
• Wynzora Cream, already approved in the US and Europe, is a topical treatment for plaque psoriasis, combining calcipotriene and betamethasone dipropionate.
• The collaboration aims to provide Canadian patients with a convenient and effective treatment option for managing plaque psoriasis symptoms.
• Wynzora Cream utilizes PAD Technology to deliver a water-based formulation designed for ease of use and improved patient adherence.
LEO Pharma Reports Double-Digit Growth Driven by Dermatology Portfolio
• LEO Pharma's revenue grew by 11% in the first nine months of 2024, with dermatology products leading the increase at 13%.
• Delgocitinib cream (Anzupgo®) received European Commission approval for chronic hand eczema and an NDA was filed in the U.S. for the same indication.
• Tralokinumab (Adtralza®/Adbry®) sales increased by 70%, driven by strong uptake in North America for the treatment of atopic dermatitis.
• An NDA for Enstilar® was submitted in China for the treatment of plaque psoriasis, expanding LEO Pharma's global presence.
Leo Pharma Seeks Approval for Enstilar Psoriasis Treatment in China
• Leo Pharma has submitted an application in China for Enstilar, a topical treatment, seeking approval for use in adult patients with plaque psoriasis.
• This marks Leo Pharma's second regulatory submission this week, highlighting the company's strategic focus on expanding its global market presence.
• Enstilar's application aims to address the needs of individuals in China affected by plaque psoriasis, a chronic inflammatory skin condition.
• The regulatory review process will assess Enstilar's safety and efficacy data to determine its suitability for the Chinese market.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath